NephroSant™ a biotechnology company dedicated to accelerating the diagnosis of early kidney damage in native and transplanted kidneys, with a mission to significantly improve...
Inhibrx, Inc., a biotechnology company with four clinical programs in development and a strong emerging pipeline, announced that the U.S. Food and Drug Administration,...
AIkido Pharma Inc. reported an improvement in the manufacturing process for its pancreatic cancer drug, DHA-dFdC, licensed from the University of Texas at Austin....
Avenge Bio, Inc., ("Avenge" or the "Company") a biotechnology company developing the LOCOcyte™ immunotherapy platform for the precision administration of potent immune effector molecules...
